降鈣素和癌胚抗原聯合檢測在甲狀腺髓樣癌診治中的意義

陳明光

[摘要] 目的 分析降鈣素和癌胚抗原聯合檢測在甲狀腺髓樣癌診治中的意義。 方法 方便收取該院20例甲狀腺髓樣癌患者作為觀察組，再收取20名健康體檢者作為對照組，收取時間在2010年2月—2015年3月，實施化學發光法檢測兩種受檢者癌胚抗原、降鈣素水平。結果 患者術后6 d癌胚抗原（3.12±0.89）ng/mL、降鈣素水平（9.59±3.29）ng/mL與術前1 d相比顯著降低，而復發時癌胚抗原、降鈣素水平與術后6 d相比，顯著升高（P<0.05），觀察組患者降鈣素（120.04±23.49）pg/mL、癌胚抗原水平（15.01±4.23）ng/mL高于對照組健康體檢者（P<0.05），聯合檢查的敏感性顯著高于單一檢查（P<0.05）。結論 降鈣素和癌胚抗原聯合檢測能提高甲狀腺髓樣癌的敏感性，利于早期治療和早期檢測，同時還能判斷患者腫瘤復發和手術效果。

[關鍵詞] 降鈣素；癌胚抗原；甲狀腺髓樣癌

[中圖分類號] R736 [文獻標識碼] A [文章編號] 1674-0742（2017）06（b）-0007-03

[Abstract] Objective To analyze the significance of combined test of Calcitonin and carcinoembryonic antigen in diagnosis and treatment of medullary carcinoma of thyroid gland. Methods Convenient selection 20 cases of patients with medullary carcinoma of thyroid gland admitted and treated in our hospital were selected as the observation group， 20 cases of healthy physical examination persons were selected as the control group and the admission time was from February 2010 to March 2015， and the calcitonin and carcinoembryonic antigen levels of the two groups were tested by the chemiluminescence method. Results On 6 d after operation， the carcinoembryonic antigen（3.12±0.89）ng/mL and calcitonin （9.59±3.29）ng/mL were obviously decreased compared with those in 1 d before operation， and the calcitonin and carcinoembryonic antigen levels at recurrence were obviously increased compared with those in 6 d after operation（P<0.05）， and the calcitonin and carcinoembryonic antigen levels in the observation group were respectively （120.04±23.49）pg/mL and （15.01±4.23）ng/mL， which were higher than those in the control group（P<0.05）， and the sensitivity of combined examination was obviously higher that of the single examination（P<0.05）. Conclusion The calcitonin and carcinoembryonic antigen can improve the sensitivity of medullary carcinoma of thyroid gland， which is conducive to the early treatment and test， and it can also determine the tumor recurrence and operation effect.

[Key words] Calcitonin； Carcinoembryonic antigen； Medullary carcinoma of thyroid gland

甲狀腺髓樣癌為臨床上常見的內分泌系統惡性腫瘤，由于該種腫瘤預后差、惡性程度高，而早發現、早診斷對甲狀腺髓樣癌患者十分重要。在臨床中甲狀腺髓樣癌無公認腫瘤標志物，而如何增加甲狀腺髓樣癌的檢出率為臨床主要研究目的[1-2]。因此，該院對降鈣素和癌胚抗原聯合檢測在甲狀腺髓樣癌診治中的意義進行分析，方便選取2010年2月—2015年3月該院收治的20例甲狀腺髓樣癌患者進行研究，現報道如下。

1 資料與方法

1.1 一般資料

方便收取該院收治的20例甲狀腺髓樣癌患者作為觀察組，再收取20名健康體檢者作為對照組。納入標準：①20例患者經病理和手術結果證實為甲狀腺髓樣癌，②兩組受檢者均簽署知情同意書，參與該次研究。排除標準：①甲狀腺疾病、其他惡性腫瘤、慢性腎病、甲狀旁腺疾病、神經內分泌腫瘤患者，②在7 d內采用口服補鈣和靜脈補鈣患者。觀察組患者；年齡在20～50歲之間，患者平均年齡為（36.01±1.16）歲，男性患者有10例、女性患者有10例。對照組；年齡在20～51歲之間，平均年齡為（37.21±1.24）歲，男性健康體檢者有9名、女性體檢者有11名。觀察組甲狀腺髓樣癌患者、對照組健康體檢者的各項資料差異無統計學意義（P>0.05），可進行對比。